Study guide
Coronary Artery Disease, Acute Coronary Syndromes & Post-MI Care
AANPCB Adult-Gerontology Primary Care Nurse Practitioner A-GNP
Track your progress as you read
Finished sections get a check mark.
1 Exam Structure, APRN Foundations & Geriatric Assessment
A-GNP Exam Logistics, Blueprint & Scoring Structure APRN Scope of Practice, Consensus Model & Interprofessional Collaboration Comprehensive Health History & Subjective Assessment Across Adult Lifespan Comprehensive Physical Examination & Clinical Assessment Skills
2 Health Assessment, Diagnostic Reasoning & Clinical Procedures
Diagnostic Reasoning, Test Interpretation & Clinical Decision-Making Screening Guidelines & Evidence-Based Health Promotion (USPSTF) Comprehensive Geriatric Assessment (CGA), Frailty & Function In-Office Clinical Procedures, ECG Interpretation & Minor Surgical Skills
3 Cardiovascular & Peripheral Vascular Disorders
Essential Hypertension & Hypertensive Urgency/Emergency Management Coronary Artery Disease, Acute Coronary Syndromes & Post-MI Care Heart Failure (HFrEF & HFpEF) Diagnosis, Staging & 4-Pillar GDMT Arrhythmias (Atrial Fibrillation), Valvular Heart Disease & PAD
4 Respiratory, HEENT & Dermatological Disorders
Asthma Management across the Adult Lifespan (GINA Guidelines) Chronic Obstructive Pulmonary Disease (COPD) Staging & Management (GOLD Guidelines) Community-Acquired Pneumonia & Lower Respiratory Tract Infections Common HEENT Disorders: Otitis, Sinusitis, Pharyngitis, Glaucoma & Macular Degeneration
5 Endocrine, Metabolic & Renal/Genitourinary Disorders
Type 2 Diabetes Mellitus Management Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Subclinical Disease Chronic Kidney Disease (CKD) Staging & Diabetic/Hypertensive Nephropathy Genitourinary Disorders: BPH, Urinary Incontinence, UTIs & Prostatitis
6 Gastrointestinal, Hematologic & Immunologic Disorders
Upper Gastrointestinal Disorders: Dyspepsia, GERD, PUD & H. pylori Lower Gastrointestinal Disorders: IBS, IBD, Diverticulitis & Colorectal Screening Liver, Biliary & Pancreatic Disorders: NAFLD/MASLD, Cirrhosis & Cholecystitis Hematologic & Immunologic Disorders: Anemias, Anticoagulation & Immunizations
7 Neurological, Cognitive & Psychiatric Disorders
Cognitive Assessment: Delirium, Dementia & Mild Cognitive Impairment Neurological Disorders: Stroke, TIA, Parkinson's Disease & Headache Syndromes Major Depressive Disorder & Anxiety Disorders in Adults & Older Adults Sleep Disorders, Insomnia & Restless Legs Syndrome
8 Geriatric Syndromes, Polypharmacy & Deprescribing
The Beers Criteria & STOPP/START Criteria for Potentially Inappropriate Medication Use Polypharmacy Management, Pharmacokinetics/Pharmacodynamics in Aging & Deprescribing Protocols Fall Risk Assessment (CDC STEADI), Gait/Balance & Mobility Impairments Pressure Injury Prevention/Staging, Urinary/Fecal Incontinence & Frailty Assessment
9 APRN Professional Practice, Ethics, Quality & Healthcare Policy
Musculoskeletal Disorders: Osteoarthritis, Osteoporosis, Gout & Back Pain Dermatological Disorders: Lesions, Skin Cancers, Infections & Rash Evaluation Palliative Care, Advance Care Planning, Pain Management & End-of-Life APRN Professional Practice, Quality Improvement, Ethics & Healthcare Policy
Coronary Artery Disease, Acute Coronary Syndromes & Post-MI Care
Key Takeaways Explain This Topic AI
Acute Coronary Syndrome (ACS) encompasses Unstable Angina, NSTEMI, and STEMI, distinguished by cardiac biomarkers (high-sensitivity troponin) and ST-segment changes on 12-lead ECG.
Atypical ACS presentations—such as shortness of breath, unexplained fatigue, weakness, epigastric discomfort, or acute confusion—are common in older adults, females, and patients with diabetes mellitus.
Primary STEMI management requires emergent reperfusion with primary Percutaneous Coronary Intervention (PCI) within 90 minutes of first medical contact at a PCI-capable facility.
Post-MI secondary prevention requires 5-pillar medical therapy: Dual Antiplatelet Therapy (DAPT with aspirin and a P2Y12 inhibitor for 12 months), high-intensity statin therapy, beta-blocker, ACE inhibitor/ARB, and aldosterone antagonist if LVEF <=40%.
High-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) is indicated for all patients with established clinical ASCVD to achieve at least a 50% reduction in LDL-C.
Last updated: July 2026
- Coronary Artery Disease, Acute Coronary Syndromes & Post-MI Care
- Pathophysiology of the Atherosclerotic Spectrum
Coronary Artery Disease (CAD) represents a spectrum ranging from stable angina to Acute Coronary Syndromes (ACS). Atherosclerosis develops through vascular endothelial injury, subendothelial accumulation of low-density lipoprotein (LDL) cholesterol, lipid oxidation, and macrophage-driven inflammation, forming fibrous plaques.
Stable angina occurs when a fixed plaque restricts coronary blood flow during increased oxygen demand (exertion, stress), causing transient subendocardial ischemia without cell necrosis. Acute Coronary Syndrome (ACS) is triggered by acute plaque erosion or rupture, exposing tissue factor and precipitating platelet aggregation and thrombosis.
Unstable Angina (UA): Partial arterial occlusion causing ischemic rest pain without cardiac biomarker elevation.
Non-ST-Elevation Myocardial Infarction (NSTEMI): Partial occlusion causing subendocardial cell necrosis, manifested by elevated troponins without persistent ST-segment elevation on 12-lead ECG.
ST-Elevation Myocardial Infarction (STEMI): Complete transmural coronary occlusion causing full-thickness myocardial necrosis, characterized by acute ST-segment elevations on ECG and biomarker elevation.
Primary and Secondary Prevention: Lipid Management
ASCVD risk is evaluated using the 10-year ASCVD Risk Estimator. According to ACC/AHA lipid guidelines, statin intensity is assigned by risk group:
Clinical ASCVD (Secondary Prevention): All patients with established CAD, prior ACS, angina, stroke/TIA, or PAD require high-intensity statin therapy regardless of baseline LDL-C.
Severe Hypercholesterolemia (LDL-C >=190 mg/dL): High-intensity statin therapy.
Diabetes Mellitus (Aged 40-75 Years): Moderate-intensity statin (or high-intensity if multiple risk factors exist).
Primary Prevention (Aged 40-75, LDL-C 70-189 mg/dL, Risk >=7.5%): Moderate- to high-intensity statin.
- Statin Intensity Daily Regimen Options Expected LDL-C Reduction
- High-Intensity Atorvastatin 40 - 80 mg; Rosuvastatin 20 - 40 mg >= 50% reduction in LDL-C
Moderate-Intensity Atorvastatin 10 - 20 mg; Rosuvastatin 5 - 10 mg; Simvastatin 20 - 40 mg 30% to 49% reduction in LDL-C
Low-Intensity Pravastatin 10 - 20 mg; Lovastatin 20 mg < 30% reduction in LDL-C
For patients with clinical ASCVD on maximum statin whose LDL-C remains >=70 mg/dL , add Ezetimibe 10 mg daily (inhibits NPC1L1 intestinal cholesterol absorption). If LDL-C remains elevated, add a PCSK9 Inhibitor (alirocumab or evolocumab).
Clinical Presentation: Classic Angina vs. Atypical Presentations
Classic angina presents as exertional substernal chest pressure radiating to the left shoulder, arm, neck, or jaw. It lasts 2 to 5 minutes and is relieved by rest or sublingual nitroglycerin. Patients may show the Levine sign (clenched fist over sternum).
Geriatric & Atypical Presentations: Older adults, female patients, and individuals with diabetes frequently present without retrosternal chest pain during acute MI. The APRN must recognize atypical "anginal equivalents":
- Unexplained acute dyspnea or tachypnea
- Profuse diaphoresis, nausea, or epigastric discomfort
- Sudden weakness, presyncope, or syncope
- Acute confusion or delirium in older adults
Physical exam during ischemia may reveal an S4 gallop, transient holosystolic murmur at the apex from papillary muscle dysfunction, or pulmonary crackles.
Diagnostic Workup: ECG, Biomarkers, and Imaging
Initial ACS evaluation requires a 12-lead ECG within 10 minutes of medical contact:
STEMI: ST-segment elevation >=1 mm in two contiguous leads, or new Left Bundle Branch Block (LBBB).
NSTEMI/UA: ST depressions, T-wave inversions, or non-specific ST changes.
Cardiac Biomarkers: High-sensitivity cardiac Troponin I (hs-cTnI) and Troponin T (hs-cTnT) are gold-standard biomarkers. Troponins rise within 2 to 3 hours, peak at 14 to 24 hours, and remain elevated for 7 to 14 days. Serial sampling at baseline and 1 to 3 hours is required. CK-MB assists in identifying early re-infarction due to clearance within 48 to 72 hours.
Diagnostic Stress Testing: Exercise stress ECG is used for stable symptomatic patients with normal baseline ECG. Pharmacologic stress imaging (regadenoson/adenosine nuclear MPI or dobutamine echocardiography) is indicated for patients with baseline ECG abnormalities or inability to exercise. Invasive coronary angiography is the definitive diagnostic gold standard.
Acute ACS Management Protocol
Immediate emergency stabilization of ACS includes:
Oxygen: Administer ONLY if SpO2 <90% or respiratory distress is present.
Aspirin: Administer 162 to 325 mg chewed immediately to inhibit platelet thromboxane A2.
Sublingual Nitroglycerin: 0.4 mg SL every 5 minutes up to 3 doses. CONTRAINDICATIONS: Right ventricular infarction or recent use of PDE-5 inhibitors (sildenafil/vardenafil within 24 hours; tadalafil within 48 hours due to refractory hypotension).
P2Y12 Inhibitors: Ticagrelor (180 mg load) or Prasugrel (60 mg load, contraindicated if prior TIA/stroke) or Clopidogrel (300-600 mg load).
Anticoagulation: Unfractionated heparin, Enoxaparin, or Bivalirudin.
Beta-Blockers: Initiate oral beta-blockers within 24 hours if hemodynamically stable.
STEMI Reperfusion Benchmarks: Primary PCI is preferred (First Medical Contact-to-balloon time <=90 minutes , or <=120 minutes if transfer required). Fibrinolytic therapy is indicated ONLY if PCI cannot be performed within 120 minutes (FMC-to-needle time <=30 minutes ).
Long-Term Post-MI Secondary Prevention (5-Pillar Medical Therapy)
Post-MI patients require guideline-directed therapy across five core pillars:
Dual Antiplatelet Therapy (DAPT): Aspirin 81 mg daily indefinitely PLUS a P2Y12 inhibitor (Ticagrelor or Clopidogrel) for at least 12 months post-ACS.
High-Intensity Statin: Atorvastatin 80 mg or Rosuvastatin 40 mg daily targeting >=50% LDL-C reduction.
Beta-Blockers: Carvedilol, Metoprolol Succinate, or Bisoprolol continued for at least 3 years (indefinitely if LVEF <=40%).
ACE Inhibitor or ARB: Indicated for LVEF <=40%, hypertension, diabetes, or CKD.
Mineralocorticoid Receptor Antagonist (MRA): Eplerenone or Spironolactone indicated if LVEF <=40% and symptomatic HF or diabetes.
Referral to outpatient Cardiac Rehabilitation is a Class I recommendation that reduces 1-year mortality by 25-30%.
Geriatric Considerations
In older adults on DAPT, bleeding risk is increased. Proton Pump Inhibitors (pantoprazole preferred over omeprazole to avoid CYP2C19 clopidogrel interaction) should be co-prescribed in high GI bleeding risk patients. Post-MI depression must be screened using the PHQ-9, as it doubles 1-year mortality.